Azithromycin use is not associated with an increased risk of death from cardiovascular causes in a general population of young and middle-aged adults


Azithromycin ( Zithromax, Zmax ) use is associated with an increased risk of death from cardiovascular causes among patients at high baseline risk. Whether azithromycin confers a similar risk in the unselected general population is unknown.

Researchers conducted a nationwide historical cohort study involving Danish adults ( 18 to 64 years of age ), linking registry data on filled prescriptions, causes of death, and patient characteristics for the period from 1997 through 2010.
Investigators estimated rate ratios for death from cardiovascular causes, comparing 1,102,050 episodes of Azithromycin use with no use of antibiotic agents ( matched in a 1:1 ratio according to propensity score, for a total of 2,204,100 episodes ) and comparing 1,102,419 episodes of Azithromycin use with 7,364,292 episodes of Penicillin V use ( an antibiotic with similar indications; analysis was conducted with adjustment for propensity score ).

The risk of death from cardiovascular causes was significantly increased with current use of Azithromycin ( defined as a 5-day treatment episode ), as compared with no use of antibiotics ( rate ratio, RR=2.85 ).

The analysis relative to an antibiotic comparator included 17 deaths from cardiovascular causes during current Azithromycin use ( crude rate, 1.1 per 1000 person-years ) and 146 during current Penicillin V use ( crude rate, 1.5 per 1000 person-years ).

With adjustment for propensity scores, current Azithromycin use was not associated with an increased risk of cardiovascular death, as compared with Penicillin V ( RR=0.93 ).

The adjusted absolute risk difference for current use of Azithromycin, as compared with Penicillin V, was -1 cardiovascular death per 1 million treatment episodes.

In conclusion, Azithromycin use was not associated with an increased risk of death from cardiovascular causes in a general population of young and middle-aged adults. ( Xagena )

Svanström HM et al, N Engl J Med 2013; 368:1704-1712

XagenaMedicine_2013



Indietro

Altri articoli

Despite limited and conflicting data on the use of Hydroxychloroquine in patients with Covid-19, the FDA ( U.S. Food and...


The aim of a study was to determine the efficacy of 1 g Azithromycin ( Zithromax, Zmax ) and alternative...


A potentially life-threatening condition called drug reaction with eosinophilia and systemic symptoms ( DRESS ) has been reported in patients...


Lower respiratory tract infection ( LRTI ) is the third leading cause of death worldwide and the first leading cause...


The current standard of care treatment for Chlamydia sometimes fails to eradicate the disease and the culprit may be in...


Chronic bacterial prostatitis ( CBP ) is frequently diagnosed in men of fertile age, and is characterized by a disabling...


The Food and Drug Administration ( FDA ) warned the public that Azithromycin ( Zithromax or Zmax ) can cause...


In a commentary published in the Canadian Medical Association Journal ( CMAJ ), Abby Lippman, an epidemiologist at McGill University...


Oral sex may be a risk factor for nongonococcal urethritis ( NGU ), one of the most common sexually transmitted...